arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Jyong Biotech Ltd.

MENS
$1.68 ▼ -0.05 (-3.18%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
4 Visible periods
7 Metrics
Peer-ranked Benchmarks
Price Chart
71
Health
Good
Bullish
auto_awesome

Analytical Summary

Jyong Biotech Ltd. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.70
info Valuation on last close. End-of-day price, Nov 5, 2026.
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
85
Financial Health ↑
67
Cash Quality ↑
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 4 years · 4 quarters